← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Arginase Deficiency

MONDO:0008814 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 31 citations openscientist · 35 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Arginase 1 deficiency (ARG1-D / argininemia) is an autosomal recessive urea cycle disorder caused by biallelic pathogenic variants in ARG1, the final urea-cycle enzyme, which hydrolyzes L-arginine to L-ornithine and urea.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 97% Arginase 1 deficiency (ARG1-D), also called argininemia or hyperargininemia, is an autosomal recessive urea cycle disorder caused by biallelic pathogenic variants in ARG1 (arginase 1), the final enzyme of the urea cycle.
Falcon states the inheritance, causal gene, and enzymatic role directly.
DOI:10.3390/app14041647, DOI:10.1016/j.eclinm.2023.102405
openscientist CONCORDANT 96% It results from partial or complete loss of arginase 1 (ARG1) enzyme activity, which catalyzes the final step of the urea cycle: the hydrolysis of L-arginine to L-ornithine and urea.
OpenScientist matches the enzymatic lesion and adds the identifier set (OMIM 207800, MONDO:0009033, ORPHA:14, chromosome 6q23.2).
PMID:41651652, PMID:36175366

Chronic hyperargininemia — not hyperammonemia — is the primary driver of disease pathology; hyperammonemia is comparatively less severe and less frequent than in other urea cycle disorders, occurring mainly during catabolic stress.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 85% with hyperammonemia occurring less frequently than in many other urea cycle disorders but still clinically relevant during catabolic stress.
Falcon frames arginine as the central driver and notes hyperammonemia is less frequent than in other UCDs but relevant under catabolic stress.
DOI:10.3390/app14041647
openscientist CONCORDANT 95% individuals with ARG1-D usually appear healthy at birth and hyperammonemia is comparatively less severe and less common. Clinical manifestations typically begin to develop in early childhood in association with high plasma arginine levels, with hyperargininemia (and not hyperammonemia) considered to be the primary driver of disease sequelae
OpenScientist explicitly designates hyperargininemia as the primary driver distinguishing ARG1-D from other UCDs.
PMID:36175366

Arginine-derived guanidino compounds accumulate and are neurotoxic, disrupting inhibitory (GABAergic/glycinergic) neurotransmission and contributing to the CNS phenotype.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 90% Guanidino compounds that are increased in hyperargininemia inhibit GABA and glycine responses on mouse neurons in cell culture.
Falcon cites guanidino-compound inhibition of GABA and glycine responses in neuronal culture as a neurotoxic mechanism.
DOI:10.1016/j.eclinm.2023.102405
openscientist CONCORDANT 85% These compounds share structural similarity with GABA and act as GABA_A receptor agonists, potentially disrupting inhibitory neurotransmission
OpenScientist agrees guanidino compounds disrupt inhibitory neurotransmission but frames the mechanism as GABA_A receptor agonism rather than inhibition of GABA/glycine responses — a mechanistic nuance, not a conflict.
PMID:36726215

The hallmark clinical phenotype is a progressive neurological syndrome with spastic diplegia/paraparesis, near-universal motor impairment, intellectual disability, and seizures, typically beginning in early childhood.

MAJORITY INTEGRATED
phenotype
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% Clinical features included motor impairment (48/48, 100%), spasticity (33/48, 69%), cognitive deficits (31/48, 65%), intellectual disability (23/36, 64%), speech and language deficits (26/48, 54%), and seizures (18/48, 38%)
OpenScientist gives prospective cohort (n=48) frequencies for each phenotype.
PMID:41651652
falcon PARTIAL 60% Progressive spastic diplegia/paraparesis (hallmark; onset often late infancy/early childhood).
Falcon agrees on the progressive spastic-diplegia hallmark and early-childhood onset, but reports different frequencies (upper motor neuron involvement ~80%, seizures ~60-75%) that diverge from OpenScientist's cohort figures (spasticity 69%, seizures 38%) — a quantitative discrepancy, not a contradiction.
DOI:10.3390/app14041647

White matter / dysmyelinating pathology and corticospinal tract degeneration provide the neural substrate for the progressive spasticity of ARG1-D.

MAJORITY INTEGRATED
pathophysiologyphenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 85% Spasticity/UMN signs are plausibly linked to corticospinal tract degeneration and dysmyelination described in the review.
Falcon links spasticity/upper-motor-neuron signs to corticospinal tract degeneration and dysmyelination.
DOI:10.3390/app14041647
openscientist PARTIAL 60% loss of arginase 1 expression results in decreased dendritic complexity, decreased excitatory and inhibitory synapse numbers, decreased intrinsic excitability, and altered synaptic transmission in layer 5 motor cortical neurons
OpenScientist also reports white matter abnormalities but emphasizes a distinct, complementary substrate — motor cortical microcircuit dysfunction in layer 5 neurons from murine models — rather than the white-matter/ corticospinal-tract framing Falcon foregrounds.
PMID:27335400

ARG1-D is ultra-rare, with a global birth prevalence of ~2.8 per 1,000,000 live births and a population prevalence of ~1.4 per 1,000,000 (~1 in 726,000).

UNANIMOUS INTEGRATED
epidemiology
ProviderStanceScoreEvidence
falcon CONCORDANT 95% Global birth prevalence of ARG1-D: 2.8 cases/1,000,000 live births
Falcon reports the 2.8/million birth prevalence and 1.4/million population prevalence figures.
DOI:10.3390/app14041647
openscientist CONCORDANT 97% Global birth prevalence for ARG1-D was estimated at 2.8 cases per million live births (country-specific estimates ranged from 0.92 to 17.5) and population prevalence to be 1.4 cases per million people (approximately 1/726,000 people)
OpenScientist reports the identical prevalence estimates with the country-specific range and gnomAD-derived source.
PMID:35236361

Pegzilarginase (PEGylated recombinant human arginase 1 enzyme therapy) is a disease-modifying treatment that markedly lowers plasma arginine (from ~354 to ~86 µmol/L at Week 24 in the phase 3 PEACE trial) versus placebo.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 95% geometric mean plasma arginine decreased from 354.0 to 86.4 µmol/L at Week 24 on pegzilarginase, versus 464.7 to 426.6 µmol/L on placebo; normalization in 90.5% vs 0%.
Falcon reports the PEACE phase 3 primary biochemical outcome with the same figures.
DOI:10.1016/j.eclinm.2023.102405
openscientist CONCORDANT 95% Pegzilarginase lowered geometric mean pArg from 354.0 μmol/L to 86.4 μmol/L at Week 24 vs 464.7 to 426.6 μmol/L for placebo
OpenScientist reports the identical PEACE result and adds long-term motor function improvement in ~95% of patients from open-label extension studies.
PMID:38292042, PMID:40714964

Advanced hepatic-correction strategies (AAV gene therapy, mRNA-LNP, CRISPR/Cas9 gene editing) restore ureagenesis and survival in arginase-deficient mouse and iPSC models, but remain preclinical.

UNANIMOUS LEAD
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 85% codon-optimized ARG1 mRNA encapsulated in LNPs led to 100% survival of arginase-deficient mice, restoring urea cycle activity and maintaining normal liver function without signs of hepatotoxicity.
Falcon summarizes preclinical mRNA-LNP, AAV gene therapy, and CRISPR approaches restoring ureagenesis in models.
DOI:10.1002/jimd.12807, DOI:10.1002/jimd.12609
openscientist CONCORDANT 80% only minimal levels of hepatic arginase activity are necessary for survival and ureagenesis in arginase-deficient mice
OpenScientist reviews AAV gene therapy, hepatocyte transplantation, and CRISPR in iPSCs, noting only ~3.3% enzyme restoration suffices for survival — all preclinical.
PMID:25474440, PMID:27898091

Because ARG1-D mimics cerebral palsy and hereditary spastic paraplegia, it is frequently misdiagnosed and should be included in the differential (and in HSP gene panels) until biochemically or genetically excluded.

SINGLE LEAD
diagnosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% Arginase 1 Deficiency should be considered in HSP differential diagnosis until biochemically/genetically excluded
OpenScientist details the overlap with cerebral palsy and HSP, the resulting diagnostic delay (mean age at diagnosis 6.4 years), and the recommendation to include ARG1 in HSP panels.
PMID:36698992, PMID:35822089
falcon SILENT —
Falcon's pathophysiology-focused report addresses newborn-screening Arg/Orn ratios but does not discuss the cerebral-palsy/HSP differential-diagnosis problem or diagnostic delay.

Narrative

Overview

Both providers frame arginase 1 deficiency (ARG1-D / argininemia) as the rarest urea cycle disorder — an autosomal recessive loss of the final urea-cycle enzyme ARG1 — in which chronic hyperargininemia, rather than hyperammonemia, drives a distinctive progressive neurological phenotype. Falcon is a focused, pathophysiology-and-mechanism report anchored on four 2024 sources; OpenScientist is a comprehensive, 15-domain report spanning genetics, phenotype frequencies, diagnostics, prognosis, treatment, and model organisms.

Agreement

The two reports converge strongly on the core biology: the ARG1 enzymatic lesion (hydrolysis of arginine to ornithine and urea), hyperargininemia as the primary disease driver with comparatively mild/infrequent hyperammonemia, guanidino- compound neurotoxicity disrupting inhibitory neurotransmission, white-matter/ corticospinal pathology underlying progressive spasticity, and early-childhood onset. They report identical epidemiology (2.8 per million birth prevalence, 1.4 per million population prevalence) and identical pivotal pegzilarginase PEACE phase 3 figures (plasma arginine 354 to 86.4 µmol/L at Week 24). Both treat AAV/ mRNA/CRISPR hepatic correction as preclinical proof-of-concept.

Divergence

Coverage and granularity differ more than substance. OpenScientist supplies prospective-cohort phenotype frequencies (motor impairment 100%, spasticity 69%, seizures 38%), the cerebral-palsy/HSP differential-diagnosis problem and diagnostic delay, detailed variant/structural biology (183 ClinVar variants, three protein-dysfunction mechanisms), founder effects, long-term pegzilarginase motor outcomes, and a full model-organism section. Falcon reports higher seizure (~60-75%) and upper-motor-neuron (~80%) frequencies than the cohort, and frames the neural substrate around white matter/corticospinal tract while OpenScientist adds a layer-5 motor-cortical-microcircuit substrate. The two also cite different MONDO identifiers (Falcon MONDO:0008814 vs OpenScientist MONDO:0009033). None of these are outright contradictions — they are quantitative discrepancies and differences of emphasis.

Integration

The concordant core biology (enzymatic lesion, hyperargininemia-as-driver, guanidino neurotoxicity, white-matter pathology), the epidemiology, the progressive spastic-diplegia phenotype, and the pegzilarginase PEACE efficacy are well supported by both reports and suitable for the disorder YAML. The KB entry retains MONDO:0008814.

Not integrated (leads)

Preclinical advanced-therapeutics (AAV/mRNA/CRISPR/hepatocyte transplantation) and the cerebral-palsy/HSP differential-diagnosis and diagnostic-delay narrative are retained as research leads pending primary-source verification rather than promoted as curated disease mechanisms.

Cross-provider synthesis comparing falcon (pathophysiology-focused, 4 anchor 2024 sources) and openscientist (comprehensive, ~50 publications). No direct contradictions were found; divergence is coverage/granularity plus minor quantitative discrepancies (seizure/UMN frequency, baseline neural substrate) and a differing MONDO identifier (Falcon MONDO:0008814 vs OpenScientist MONDO:0009033; the KB entry uses MONDO:0008814). best_matching_text values are verbatim excerpts from the cited report files; literature evidence snippets are intentionally unpopulated pending fetch-reference verification.